For many patients with terminal/advanced cardiac failure, heart transplantation is the most
effective, durable treatment option, and offers the best prospects for a high quality of life. The …

Survival of pig cardiac xenografts in a non-human primate (NHP) model has improved
significantly over the last 4 years with the introduction of costimulation blockade-based …

Background The demand for donated human hearts far exceeds the number available.
Xenotransplantation of genetically modified porcine organs provides an alternative. In 2000 …

Approximately 65 million adults globally have heart failure, and the prevalence is expected
to increase substantially with ageing populations. Despite advances in pharmacological and …

Reflecting on the first genetically engineered pig-to-human heart transplantation in this
Clinical Outlook article, we discuss the likely future of cardiac xenotransplantation. Initial …

Consistent survival of life-supporting pig heart xenograft recipients beyond 90 days was
recently reported using genetically modified pigs and a clinically applicable drug treatment …

Bauer A, Postrach J, Thormann M, Blanck S, Faber C, Wintersperger B, Michel S, Abicht J‐
M, Christ F, Schmitz C, Schmoeckel M, Reichart B, Brenner P. First experience with …

Significant progress in understanding and overcoming cardiac xenograft rejection using a
clinically relevant large animal pig-to-baboon model has accelerated in recent years. This …

Heart transplantation is the only long-lasting lifesaving option for patients with terminal
cardiac failure. The number of available human organs is however far below the actual …

Cardiac xenotransplantation has recently taken an important step towards clinical reality. In
anticipation of the “first-in-human” heart xenotransplantation trial, we propose a set of patient …